Date: 2015-10-06
Type of information: Construction of new premises
Compound: new facility at Milton Park
Company: Adaptimmune (UK)
Therapeutic area: Cancer - Oncology
Type agreement: construction of new premises
Action mechanism:
Disease:
Details: * On October 6, 2015, Adaptimmune announced plans to expand its research and development operation into a major new purpose-built facility at Milton Park, Oxfordshire. Construction of Adaptimmune’s 67,000 square foot ‘Enterprise Zone’ building is already under way following a traditional groundbreaking ceremony. The flagship facility will provide laboratory space with associated offices, meeting rooms and a café area to accommodate a team of around 200 highly-skilled research and development specialists. The new building is designed to support the Company’s continuing growth of its research and development operation and is scheduled for delivery in late 2016.
Adaptimmune has signed a 25-year agreement with break options to lease the building from developer MEPC, which owns Milton Park, one of Europe’s largest business parks and home to over 7,500 employees and 250 organizations.
Adaptimmune was established at Milton Park in 2008 in a small laboratory. Following its foundation in the U.K., the company launched its U.S operation in 2011 after a longstanding research collaboration with the University of Pennsylvania. Adaptimmune is currently running five Phase I/II trials in multiple cancers across the U.S. targeting the NY-ESO-1 cancer antigen in both solid and hematologic cancers with promising early results. Adaptimmune also has an IND open with its second therapeutic candidate, MAGE-A10, and a third candidate in planning for IND submission in 2016. In May 2015, the company achieved a successful IPO on NASDAQ, generating net proceeds in excess of $176 million, and is advancing a pipeline of therapeutic candidates based on its proprietary T-cell engineering platform.
Financial terms:
Latest news:
